<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764790</url>
  </required_header>
  <id_info>
    <org_study_id>111751</org_study_id>
    <nct_id>NCT00764790</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children</brief_title>
  <official_title>Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline
      Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine)
      in children, 6 to 35 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains</measure>
    <time_frame>Day 0 (PRE), Day 28 or Day 56 (POST)</time_frame>
    <description>GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted</measure>
    <time_frame>Day 28 or Day 56</time_frame>
    <description>Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer &lt; 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects</measure>
    <time_frame>Day 0 (PRE), Day 28 or Day 56 (POST)</time_frame>
    <description>A seroprotected subject is a subject with a serum anti-HA titer
≥ 1:40
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor</measure>
    <time_frame>Day 28 or Day 56</time_frame>
    <description>Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0).
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During a 4-day follow-up period after vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During a 4-day follow-up period after vaccination</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>During a 28-day follow-up period after vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)</measure>
    <time_frame>During the entire study (Day 0 until Month 6)</time_frame>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Rare Serious Events</measure>
    <time_frame>During the entire study (Day 0 until Month 6)</time_frame>
    <description>Rare serious events have an occurrence rate of 1/300 (0.3%).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3317</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluarix Dose A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Dose B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.</description>
    <arm_group_label>Fluarix Dose B Group</arm_group_label>
    <arm_group_label>Fluarix Dose A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.</description>
    <arm_group_label>Fluzone Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female child aged 6 to 35 months at the time of the first vaccination;
             children who may or may not have had previous administration of influenza vaccine in a
             previous season are acceptable.

          -  Subjects having a parent/guardian who the investigator believes can and will comply
             with the requirements of the protocol.

          -  Written informed consent obtained from the subject's parent/guardian.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the administration of the study vaccine, or planned use during the study
             period. Routine, registered childhood vaccinations are not an exclusion criterion.

          -  History of hypersensitivity to any vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine.

          -  Acute disease at the time of enrolment.

          -  History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated
             influenza virus vaccine.

          -  Receipt of an influenza vaccine outside of this study, during current (2008-09) flu
             season.

          -  Administration of immunoglobulins and/or blood products within the 3 months preceding
             the first dose of study vaccine or planned administration during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benton</city>
        <state>Arkansas</state>
        <zip>72019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Conway</city>
        <state>Arkansas</state>
        <zip>72034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeKalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cortland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austintown</city>
        <state>Ohio</state>
        <zip>44515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roy</city>
        <state>Utah</state>
        <zip>84067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordon</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico city</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>6720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Mexico</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>February 25, 2010</results_first_submitted>
  <results_first_submitted_qc>June 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2010</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111751</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluarix Dose A Group</title>
          <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Dose B Group</title>
          <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="P3">
          <title>Fluzone Group</title>
          <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1107"/>
                <participants group_id="P2" count="1106"/>
                <participants group_id="P3" count="1104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1069"/>
                <participants group_id="P2" count="1065"/>
                <participants group_id="P3" count="1074"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluarix Dose A Group</title>
          <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Dose B Group</title>
          <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="B3">
          <title>Fluzone Group</title>
          <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1107"/>
            <count group_id="B2" value="1106"/>
            <count group_id="B3" value="1104"/>
            <count group_id="B4" value="3317"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" spread="8.07"/>
                    <measurement group_id="B2" value="20.9" spread="8.42"/>
                    <measurement group_id="B3" value="21.0" spread="8.23"/>
                    <measurement group_id="B4" value="20.9" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="539"/>
                    <measurement group_id="B2" value="517"/>
                    <measurement group_id="B3" value="560"/>
                    <measurement group_id="B4" value="1616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="589"/>
                    <measurement group_id="B3" value="544"/>
                    <measurement group_id="B4" value="1701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains</title>
        <description>GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
        <time_frame>Day 0 (PRE), Day 28 or Day 56 (POST)</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains</title>
          <description>GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
          <units>titre</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1018"/>
                <count group_id="O2" value="1016"/>
                <count group_id="O3" value="1031"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane (PRE) (N=1017; 1013; 1030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.7" upper_limit="11.1"/>
                    <measurement group_id="O2" value="10.6" lower_limit="9.8" upper_limit="11.4"/>
                    <measurement group_id="O3" value="10.9" lower_limit="10.1" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane (POST) (N=1018; 1016; 1031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.1" lower_limit="93.8" upper_limit="120.1"/>
                    <measurement group_id="O2" value="131.6" lower_limit="116.3" upper_limit="148.9"/>
                    <measurement group_id="O3" value="232.4" lower_limit="214.0" upper_limit="252.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay (PRE) (N=1017; 1013; 1030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="11.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="11.2" lower_limit="10.2" upper_limit="12.2"/>
                    <measurement group_id="O3" value="11.6" lower_limit="10.7" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay (POST) (N=1018; 1016; 1031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.6" lower_limit="113.3" upper_limit="139.3"/>
                    <measurement group_id="O2" value="158.7" lower_limit="143.9" upper_limit="175.2"/>
                    <measurement group_id="O3" value="280.3" lower_limit="260.3" upper_limit="301.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida (PRE) (N=1017; 1013; 1030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="7.9" upper_limit="9.0"/>
                    <measurement group_id="O2" value="8.9" lower_limit="8.3" upper_limit="9.6"/>
                    <measurement group_id="O3" value="8.3" lower_limit="7.7" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida (POST) (N=1018; 1016; 1031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.0" lower_limit="103.4" upper_limit="123.4"/>
                    <measurement group_id="O2" value="164.4" lower_limit="150.2" upper_limit="180.1"/>
                    <measurement group_id="O3" value="176.4" lower_limit="162.3" upper_limit="191.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted</title>
        <description>Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer &lt; 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
        <time_frame>Day 28 or Day 56</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted</title>
          <description>Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer &lt; 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1017"/>
                <count group_id="O2" value="1013"/>
                <count group_id="O3" value="1030"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="636"/>
                    <measurement group_id="O2" value="699"/>
                    <measurement group_id="O3" value="929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747"/>
                    <measurement group_id="O2" value="808"/>
                    <measurement group_id="O3" value="988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="812"/>
                    <measurement group_id="O2" value="864"/>
                    <measurement group_id="O3" value="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects</title>
        <description>A seroprotected subject is a subject with a serum anti-HA titer
≥ 1:40
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
        <time_frame>Day 0 (PRE), Day 28 or Day 56 (POST)</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects</title>
          <description>A seroprotected subject is a subject with a serum anti-HA titer
≥ 1:40
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1018"/>
                <count group_id="O2" value="1016"/>
                <count group_id="O3" value="1031"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane (PRE) (N=1017; 1013; 1030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane (POST) (N=1018; 1016; 1031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="699"/>
                    <measurement group_id="O2" value="754"/>
                    <measurement group_id="O3" value="986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay (PRE) (N=1017; 1013; 1030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay (POST) (N=1018; 1016; 1031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="788"/>
                    <measurement group_id="O2" value="846"/>
                    <measurement group_id="O3" value="1012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida (PRE) (N=1017; 1013; 1030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="181"/>
                    <measurement group_id="O3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida (POST) (N=1018; 1016; 1031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872"/>
                    <measurement group_id="O2" value="902"/>
                    <measurement group_id="O3" value="935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor</title>
        <description>Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0).
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
        <time_frame>Day 28 or Day 56</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor</title>
          <description>Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0).
Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity</population>
          <units>fold increase</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1017"/>
                <count group_id="O2" value="1013"/>
                <count group_id="O3" value="1030"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="9.2" upper_limit="11.4"/>
                    <measurement group_id="O2" value="12.4" lower_limit="11.2" upper_limit="13.7"/>
                    <measurement group_id="O3" value="21.4" lower_limit="19.9" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.6" upper_limit="11.3"/>
                    <measurement group_id="O2" value="14.2" lower_limit="13.1" upper_limit="15.4"/>
                    <measurement group_id="O3" value="24.1" lower_limit="22.6" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="12.4" upper_limit="14.5"/>
                    <measurement group_id="O2" value="18.4" lower_limit="17.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="21.4" lower_limit="19.7" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During a 4-day follow-up period after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, including all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, including all vaccinated subjects for whom data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1081"/>
                <count group_id="O2" value="1086"/>
                <count group_id="O3" value="1090"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                    <measurement group_id="O2" value="406"/>
                    <measurement group_id="O3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.</description>
        <time_frame>During a 4-day follow-up period after vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, including all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, including all vaccinated subjects for whom data were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1080"/>
                <count group_id="O2" value="1086"/>
                <count group_id="O3" value="1090"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="317"/>
                    <measurement group_id="O3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="387"/>
                    <measurement group_id="O3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                    <measurement group_id="O2" value="273"/>
                    <measurement group_id="O3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product</description>
        <time_frame>During a 28-day follow-up period after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1107"/>
                <count group_id="O2" value="1106"/>
                <count group_id="O3" value="1104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565"/>
                    <measurement group_id="O2" value="541"/>
                    <measurement group_id="O3" value="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders</description>
        <time_frame>During the entire study (Day 0 until Month 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)</title>
          <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1107"/>
                <count group_id="O2" value="1106"/>
                <count group_id="O3" value="1104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Rare Serious Events</title>
        <description>Rare serious events have an occurrence rate of 1/300 (0.3%).</description>
        <time_frame>During the entire study (Day 0 until Month 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Dose A Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Dose B Group</title>
            <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Group</title>
            <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Rare Serious Events</title>
          <description>Rare serious events have an occurrence rate of 1/300 (0.3%).</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1107"/>
                <count group_id="O2" value="1106"/>
                <count group_id="O3" value="1104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchiolitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluarix Dose A Group</title>
          <description>Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Dose B Group</title>
          <description>Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
        <group group_id="E3">
          <title>Fluzone Group</title>
          <description>Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children &gt;12 months of age) or in the anterolateral thigh (children &lt;12 months of age).
* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Injury corneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Idiopathic urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="565" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="541" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="562" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="403" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="406" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="363" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="253" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="317" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="298" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="387" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="375" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="270" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="1104"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1107"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1106"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="1104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

